MESA LABORATORIES INC /CO/ Debt Disclosure
Note 8. Indebtedness
Credit Facility
Our secured credit agreement matures in April 2029 and includes:
| (i) | A revolving credit facility with an aggregate principal amount of up to $125,000 (the "Revolver"), |
| (ii) | A term loan with a maximum principal amount of $75,000, which is subject to escalating quarterly principal payments (the "Term Loan"), |
| (iii) | A swingline loan with an aggregate principal amount not exceeding $5,000, and, |
| (iv) | Letters of credit with an aggregate stated amount not exceeding $2,500 at any time. |
We refer to the agreement in whole as the “Credit Facility.”
Borrowings under our Credit Facility bear interest at a SOFR rate or a base rate, plus an applicable spread that varies with our total net leverage ratio. On October 10, 2025 we amended the Credit Facility to reduce the range of the spread from 1.5% - 3.0% to 1.25% - 2.50%.
The weighted average interest rate on borrowings under the Credit Facility as of March 31, 2026 was 5.9%.
The financial covenants in the Credit Facility include a maximum leverage ratio of 4.00 to 1.00 on each of the quarterly testing dates between March 31, 2025 and March 31, 2026 and 3.5 to 1.0 on each testing date thereafter. The Credit Facility also stipulates a minimum fixed charge coverage ratio of 1.25 to 1.0. Other covenants include restrictions on our ability to incur debt, grant liens, make fundamental changes to our business as defined in the contract, engage in certain transactions with affiliates, or conduct asset sales. As of March 31, 2026, we were in compliance with all required covenants under the terms of the Credit Facility.
Term Loan
We are required to make quarterly principal payments on the Term Loan. During the year ended March 31, 2026, we made required principal payments on the Term Loan of $3,750. For the fiscal years ending March 31, required future principal debt payments on the Term Loan are as follows:
| Fiscal Year | Amount | |||
| 2027 | $ | 5,625 | ||
| 2028 | 5,625 | |||
| 2029 | 7,500 | |||
| 2030 | 48,750 | |||
| Total principal remaining | $ | 67,500 | ||
Unamortized debt issuance costs related to the Term Loan are reflected as a discount to the debt’s carrying value in our Consolidated Balance Sheets and are being amortized to interest expense through maturity. The net carrying amount of the Term Loan was as follows:
| March 31,2026 | March 31, 2025 | |||||||
| Term Loan (% and % as of March 31, 2026 and 2025, respectively) | $ | 67,500 | $ | 71,250 | ||||
| Less: debt issuance costs | (518 | ) | (598 | ) | ||||
| Less: current portion | (5,625 | ) | (3,750 | ) | ||||
| Noncurrent portion | $ | 61,357 | $ | 66,902 | ||||
Revolver
As of March 31, 2026, the outstanding balance under our Revolver was $84,500, and $40,500 was available for borrowing.
We are obligated to pay quarterly unused commitment fees of between 0.20% and 0.35% of the Revolver’s aggregate principal amount, based on our leverage ratio. We incurred unused commitment fees of $157 and $269 for the years ended March 31, 2026, and March 31, 2025, respectively.
The balance of unamortized customary lender fees related to the Revolver was $1,018 and $1,203 as of March 31, 2026 and 2025, respectively. The lender fees are being amortized to interest expense through maturity.
Convertible Notes
On August 12, 2019, we issued an aggregate principal amount of $172,500 of Notes bearing interest at a rate of 1.375%. Debt issuance costs related to the Notes, consisting of $2,925 of commissions payable to the initial purchasers and $152 of third-party offering costs, were recorded as a reduction to the carrying amount of the Notes and amortized to interest expense over the life of the Notes.
During fiscal year 2025, we repurchased $75,000 principal amount of the Notes in privately negotiated transactions, which resulted in the recognition of a gain on extinguishment of $2,887 recorded in other income for the year ended March 31, 2025.
The Notes matured on August 15, 2025. Upon maturity, we settled the remaining aggregate principal balance of $97,500, as well as $670 of accrued interest, in cash by drawing $97,000 under our Revolver and using $1,170 of cash on hand.
The historical net carrying amount of the Notes was as follows:
| March 31, 2025 | ||||
| Principal outstanding | $ | 97,500 | ||
| Unamortized debt issuance costs | (203 | ) | ||
| Net carrying value | $ | 97,297 | ||
We recognized interest expense on the Notes as follows:
| Year Ended March 31, | ||||||||||||
| 2026 | 2025 | 2024 | ||||||||||
| Coupon interest expense at 1.375% | $ | 503 | $ | 1,372 | $ | 2,372 | ||||||
| Amortization of debt issuance costs | 203 | 546 | 926 | |||||||||
| Total interest on the Notes | $ | 706 | $ | 1,918 | $ | 3,298 | ||||||
Want the next MESA LABORATORIES INC /CO/ debt disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment MESA LABORATORIES INC /CO/'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2026 | Jun 3, 2026 | Showing above |
| 2025 | May 28, 2025 | |
| 2024 | Jun 28, 2024 | |
| 2023 | May 30, 2023 | |
| 2022 | May 31, 2022 | |
| 2021 | Jun 1, 2021 | |
| 2020 | Jun 1, 2020 | |
| 2019 | Jun 3, 2019 | |
| 2018 | Jun 5, 2018 | |
| 2017 | Jun 7, 2017 | |
| 2016 | Jun 6, 2016 | |
About Debt Disclosures
Debt disclosures detail a company's borrowing structure — the types of instruments, interest rates, maturity schedule, and covenant restrictions that define its financial obligations and flexibility. This section is essential for assessing refinancing risk, interest rate exposure, and the margin of safety against financial distress.
Key signals: the maturity schedule reveals concentration risk — large maturities within 1-2 years during tight credit markets can force dilutive refinancing or asset sales. Compare the fair value of debt against carrying amount to gauge whether the market views the company's credit risk differently than the balance sheet suggests. Watch covenant compliance disclosures for tightening cushions, especially leverage and interest coverage ratios. Variable-rate debt exposure quantifies sensitivity to interest rate changes. Secured versus unsecured mix affects recovery rates and future borrowing capacity. Compare net debt-to-EBITDA against industry peers and covenant limits to assess financial health.